HomeBUSINESS
BUSINESS

Kyowa Kirin Kicks Off Japan PIII for Regpara Follow-Up Evocalcet
(Nov.1.2017)

Kyowa Hakko Kirin said on October 30 that it has commenced a PIII open-label trial in Japan for the calcimimetic agent evocalcet (KHK7580) for the treatment of hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism ...
(LOG IN FOR FULL STORY)

News Calendar